Payment overview · 2025
General Payments
$209.35
3 reported records · 3 companies
Healthcare provider profile · identity verified
Matthew Gregory Smith, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ST PETERSBURG, FL · NPI 1235121724
Verified facts
What the public records show
CMS Open Payments records show Matthew Gregory Smith, M.D. received $209.35 in general payments during 2025 across 3 reported records.
Abbott Laboratories accounted for 60.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $126.00 | 60.2% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$69.06 | 33.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.29 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $209.35 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $126.00 | 1 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $69.06 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 42 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
54 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 897 | 251 |
| Levothyroxine Sodium | Levothyroxine Sodium | 831 | 227 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 812 | 245 |
| Amlodipine Besylate | Amlodipine Besylate | 725 | 210 |
| Lisinopril | Lisinopril | 711 | 209 |
| Metformin Hcl | Metformin Hcl | 668 | 209 |
| Alprazolam | Alprazolam | 645 | 127 |
| Omeprazole | Omeprazole | 599 | 174 |
| Losartan Potassium | Losartan Potassium | 576 | 161 |
| Montelukast Sodium | Montelukast Sodium | 425 | 122 |
| Tramadol Hcl | Tramadol Hcl | 416 | 94 |
| Gabapentin | Gabapentin | 379 | 113 |
| Simvastatin | Simvastatin | 369 | 106 |
| Temazepam | Temazepam | 347 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 345 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 313 | 99 |
| Hydrochlorothiazide | Hydrochlorothiazide | 304 | 92 |
| Trazodone Hcl | Trazodone Hcl | 290 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 276 | 89 |
| Famotidine | Famotidine | 263 | 84 |
| Furosemide | Furosemide | 262 | 88 |
| Tamsulosin Hcl | Tamsulosin Hcl | 240 | 82 |
| Metoprolol Tartrate | Metoprolol Tartrate | 238 | 78 |
| Metformin Hcl Er | Metformin Hcl | 234 | 76 |
| Duloxetine Hcl | Duloxetine Hcl | 211 | 62 |
| Allopurinol | Allopurinol | 199 | 58 |
| Lorazepam | Lorazepam | 187 | 36 |
| Carvedilol | Carvedilol | 186 | 50 |
| Pioglitazone Hcl | Pioglitazone Hcl | 186 | 49 |
| Glimepiride | Glimepiride | 183 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 179 | 58 |
| Pravastatin Sodium | Pravastatin Sodium | 175 | 52 |
| Eliquis | Apixaban | 174 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 172 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 167 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 159 | 28 |
| Ezetimibe | Ezetimibe | 153 | 51 |
| Diazepam | Diazepam | 150 | 35 |
| Sertraline Hcl | Sertraline Hcl | 145 | 47 |
| Potassium Chloride | Potassium Chloride | 136 | 37 |
| Jardiance | Empagliflozin | 134 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 133 | 37 |
| Spironolactone | Spironolactone | 124 | 40 |
| Atenolol | Atenolol | 122 | 34 |
| Clonazepam | Clonazepam | 121 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 117 | 43 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 116 | 36 |
| Pregabalin | Pregabalin | 116 | 32 |
| Azithromycin | Azithromycin | 114 | 94 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 113 | 91 |
| Ibuprofen | Ibuprofen | 112 | 43 |
| Fenofibrate | Fenofibrate | 107 | 30 |
| Meloxicam | Meloxicam | 99 | 43 |
| Baclofen | Baclofen | 96 | 36 |
| Acarbose | Acarbose | 94 | 30 |
| Donepezil Hcl | Donepezil Hcl | 89 | 27 |
| Celecoxib | Celecoxib | 88 | 34 |
| Cephalexin | Cephalexin | 88 | 55 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 86 | 24 |
| Valsartan | Valsartan | 85 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 84 | 23 |
| Nifedipine Er | Nifedipine | 84 | 24 |
| Prednisone | Prednisone | 80 | 48 |
| Sildenafil Citrate | Sildenafil Citrate | 80 | 19 |
| Bupropion Xl | Bupropion Hcl | 77 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 21 |
| Mounjaro | Tirzepatide | 75 | 14 |
| Ondansetron Odt | Ondansetron | 74 | 24 |
| Finasteride | Finasteride | 72 | 21 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 70 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 70 | 22 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 67 | 19 |
| Xarelto | Rivaroxaban | 67 | 15 |
| Alendronate Sodium | Alendronate Sodium | 65 | 21 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 64 | 55 |
| Meclizine Hcl | Meclizine Hcl | 61 | 24 |
| Testosterone Cypionate | Testosterone Cypionate | 61 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 15 |
| Buspirone Hcl | Buspirone Hcl | 58 | 15 |
| Clonidine Hcl | Clonidine Hcl | 58 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 58 | 19 |
| Methylprednisolone | Methylprednisolone | 57 | 50 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 40 |
| Nystatin | Nystatin | 54 | 29 |
| Symbicort | Budesonide/Formoterol Fumarate | 54 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 18 |
| Lovastatin | Lovastatin | 52 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 21 |
| Estradiol | Estradiol | 50 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 28 |
| Fluconazole | Fluconazole | 46 | 35 |
| Gemfibrozil | Gemfibrozil | 46 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 15 |
| Acyclovir | Acyclovir | 45 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 42 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 43 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 16 |
| Topiramate | Topiramate | 43 | 12 |
| Farxiga | Dapagliflozin Propanediol | 42 | 13 |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Ramipril | Ramipril | 41 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 40 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 39 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | 16 |
| Warfarin Sodium | Warfarin Sodium | 39 | 13 |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 38 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | 12 |
| Amoxicillin | Amoxicillin | 36 | 29 |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | 13 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 34 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 33 | 11 |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | 11 |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | 11 |
| Folic Acid | Folic Acid | 30 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Carisoprodol | Carisoprodol | 29 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Scopolamine | Scopolamine | 29 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Cefdinir | Cefdinir | 27 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Telmisartan | Telmisartan | 27 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | suppressed |
| Sotalol | Sotalol Hcl | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Lubiprostone | Lubiprostone | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Dexamethasone | Dexamethasone | 22 | 17 |
| Dutasteride | Dutasteride | 22 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Anastrozole | Anastrozole | 19 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Benzonatate | Benzonatate | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 14 |
| Tradjenta | Linagliptin | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Cholestyramine Light | Cholestyramine | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $209.35 · 3 records | Abbott Laboratories | ENDURANT IIS, FARXIGA, TRICLIP | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error